Ahead of FDA decision on BTK drug, Amgen-partnered BeiGene scores China OK for PD-1

China is reportedly approving its 6th PD-1(L)1 drug in just over a year — and Amgen will be pleased with this one.

The OK for tislelizumab would be the first marketed product to be developed by BeiGene, the eminent Beijing-based biotech that Amgen recently took a $2.7 billion stake in.